THE LIMITS OF BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDER
- 1 March 2001
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 165 (3), 745-756
- https://doi.org/10.1016/s0022-5347(05)66518-4
Abstract
No abstract availableThis publication has 101 references indexed in Scilit:
- EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDERJournal of Urology, 2000
- THE VALUE OF A SECOND TRANSURETHRAL RESECTION IN EVALUATING PATIENTS WITH BLADDER TUMORSJournal of Urology, 1999
- WHAT IS THE OPTIMAL REGIMEN FOR INTRAVESICAL BCG THERAPYJournal of Urology, 1999
- Extravesical Involvement in Patients with Bladder Carcinoma In Situ: Biological and Therapy ImplicationsJournal of Urology, 1996
- Integral Photodynamic Treatment of Refractory Superficial Bladder CancerJournal of Urology, 1995
- Outcome in Carcinoma in situ of Bladder Treated with Intravesical Bacille Calmette‐GuérinBJU International, 1992
- Urological Audit: the Role for an Aggressive Approach to High Grade Superficial Bladder TumoursBJU International, 1992
- p53, guardian of the genomeNature, 1992
- A fluorescence study examining how 14-valerate side chain substitution modulates anthracycline binding to small unilamellar phospholipid vesiclesBiochimica et Biophysica Acta (BBA) - Biomembranes, 1989
- Photodynamic Therapy with Hematoporphyrin Derivative in the Treatment of Superficial Transitional-Cell Carcinoma of the BladderThe New England Journal of Medicine, 1987